(2009) Cancer Facts & Figures, , American Cancer Society. Atlanta: American Cancer Society
Louis, D.N., Ohgaki, H., Wiestler, O.D., The 2007 WHO classification of tumours of the central nervous system (2007) Acta Neuropathol, 114, p. 97
Scarabino, T., Popolizio, T., Trojsi, F., Role of advanced MR imaging modalities in diagnosing cerebral gliomas (2009) Radiol Med, 114, p. 448
Gallagher, B.M., Fowler, J.S., Gutterson, N.I., Metabolic trapping as a principle of oradiopharmaceutical design: Some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-Dglucose (1978) J Nucl Med, 19, p. 1154
Nishioka, T., Oda, Y., Seino, Y., Distribution of the glucose transporters in human brain tumors (1992) Cancer Res, 52, p. 3972
Weber, G., Enzymology of cancer cells (first of two parts) (1977) N Engl J Med, 296, p. 486
Di Chiro, G., Delapaz, R.L., Brooks, R.A., Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography (1982) Neurology, 32, p. 1323
Herholz, K., Pietrzyk, U., Voges, J., Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study (1993) J Neurosurg, 79, p. 853
Stockhammer, F., Thomale, U.W., Plotkin, M., Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas (2007) J Neurosurg, 106, p. 633
Dancey, J.E., Curiel, R., Purvis, J., Evaluating temsirolimus activity in multiple tumors: A review of clinical trials (2009) Semin Oncol, 36 (SUPPL. 3), pp. S46
Wei, L.H., Su, H., Hildebrandt, I.J., Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma (2008) Clin Cancer Res, 14, p. 3416
Delbeke, D., Meyerowitz, C., Lapidus, R.L., Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET (1995) Radiology, 195, p. 47
Kim, C.K., Alavi, J.B., Alavi, A., New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose (1991) J Neurooncol, 10, p. 85
Hustinx, R., Smith, R.J., Benard, F., Can the standardized uptake value characterize primary brain tumors on FDG-PET? (1999) Eur J Nucl Med, 26, p. 1501
Lilja, A., Bergstrom, K., Hartvig, P., Dynamic study of supratentorial gliomas with L-methyl-11Cmethionine and positron emission tomography (1985) AJNR Am J Neuroradiol, 6, p. 505
Vaalburg, W., Coenen, H.H., Crouzel, C., Amino acids for the measurement of protein synthesis in vivo by PET (1992) Int J Rad Appl Instrum B, 19, p. 227
Coenen, H.H., Kling, P., Stocklin, G., Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis (1989) J Nucl Med, 30, p. 1367
Luxen, A., Perlmutter, M., Bida, G.T., Remote, semiautomated production of 6-[18F]fluoro-Ldopa for human studies with PET (1990) Int J Rad Appl Instrum A, 41, p. 275
Tomiyoshi, K., Amed, K., Muhammad, S., Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: Position 2- and 3-L-18Falpha- methyltyrosine using a separation and purification system (1997) Nucl Med Commun, 18, p. 169
Wester, H.J., Herz, M., Weber, W., Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging (1999) J Nucl Med, 40, p. 205
Ishiwata, K., Kubota, K., Murakami, M., A comparative study on protein incorporation of L- [methyl-3H]methionine L-[1-14C]leucine and L-2- [18F]fluorotyrosine in tumor bearing mice (1993) Nucl Med Biol, 20, p. 895
Roelcke, U., Radu, E.W., Von Ammon, K., Alteration of blood-brain barrier in human brain tumors: Comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET (1995) J Neurol Sci, 132, p. 20
Lahoutte, T., Caveliers, V., Camargo, S.M., SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its trans-stimulation (2004) J Nucl Med, 45, p. 1591
Langen, K.J., Hamacher, K., Weckesser, M., O-(2-[18F]fluoroethyl)-L-tyrosine: Uptake mechanisms and clinical applications (2006) Nucl Med Biol, 33, p. 287
Langen, K.J., Jarosch, M., Muhlensiepen, H., Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas (2003) Nucl Med Biol, 30, p. 501
Toyohara, J., Waki, A., Takamatsu, S., Basis of FLT as a cell proliferation marker: Comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines (2002) Nucl Med Biol, 29, p. 281
Degrado, T.R., Baldwin, S.W., Wang, S., Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers (2001) J Nucl Med, 42, p. 1805
Hara, T., 18F-fluorocholine: A new oncologic PET tracer (2001) J Nucl Med, 42, p. 1815
Hara, T., Kosaka, N., Shinoura, N., PET imaging of brain tumor with [methyl-11C]choline (1997) J Nucl Med, 38, p. 842
Wald, L.L., Nelson, S.J., Day, M.R., Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy (1997) J Neurosurg, 87, p. 525
Decristoforo, C., Knopp, R., Von Guggenberg, E., A fully automated synthesis for the preparation of 68Ga-labelled peptides (2007) Nucl Med Commun, 28, p. 870
Henze, M., Schuhmacher, J., Hipp, P., PET imaging of somatostatin receptors using [68GA]DOTA-DPhe1-Tyr3- octreotide: First results in patients with meningiomas (2001) J Nucl Med, 42, p. 1053
Kaschten, B., Stevenaert, A., Sadzot, B., Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine (1998) J Nucl Med, 39, p. 778
Ogawa, T., Inugami, A., Hatazawa, J., Clinical positron emission tomography for brain tumors: Comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine (1996) AJNR Am J Neuroradiol, 17, p. 345
Kosaka, N., Tsuchida, T., Uematsu, H., 18F-FDG PET of common enhancing malignant brain tumors (2008) AJR Am J Roentgenol, 190, pp. W365
Kitajima, K., Nakamoto, Y., Okizuka, H., Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors (2008) Ann Nucl Med, 22, p. 595
Posther, K.E., McCall, L.M., Harpole Jr., D.H., Yield of brain 18F-FDG PET in evaluating patients with potentially operable nonsmall cell lung cancer (2006) J Nucl Med, 47, p. 1607
Ogawa, T., Shishido, F., Kanno, I., Cerebral glioma: Evaluation with methionine PET (1993) Radiology, 186, p. 45
Braun, V., Dempf, S., Weller, R., Cranial neuronavigation with direct integration of 11Cmethionine positron emission tomography (PET) data - Results of a pilot study in 32 surgical cases (2002) Acta Neurochir (Wien), 144, p. 777
Herholz, K., Holzer, T., Bauer, B., 11C-methionine PET for differential diagnosis of low-grade gliomas (1998) Neurology, 50, p. 1316
Kracht, L.W., Miletic, H., Busch, S., Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: Local comparison with stereotactic histopathology (2004) Clin Cancer Res, 10, p. 7163
Yamane, T., Sakamoto, S., Senda, M., Clinical impact of (11C)-methionine PETon expected management of patients with brain neoplasm (2010) Eur J Nucl Med Mol Imaging, 37, pp. 685-690
Galldiks, N., Kracht, L.W., Berthold, F., [11C]-Lmethionine positron emission tomography in the management of children and young adults with brain tumors (2010) J Neurooncol, 96, p. 231
Pauleit, D., Floeth, F., Hamacher, K., O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas (2005) Brain, 128, p. 678
Pauleit, D., Stoffels, G., Bachofner, A., Comparison of 18F-FET and 18F-FDG PET in brain tumors (2009) Nucl Med Biol, 36, p. 779
Floeth, F.W., Pauleit, D., Sabel, M., 18F-FET PET differentiation of ring-enhancing brain lesions (2006) J Nucl Med, 47, p. 776
Becherer, A., Karanikas, G., Szabo, M., Brain tumour imaging with PET: A comparison between [18F]fluorodopa and [11C]methionine (2003) Eur J Nucl Med Mol Imaging, 30, p. 1561
Chen, W., Silverman, D.H., Delaloye, S., 18F-FDOPA PET imaging of brain tumors: Comparison study with 18F-FDG PET and evaluation of diagnostic accuracy (2006) J Nucl Med, 47, p. 904
De Witte, O., Goldberg, I., Wikler, D., Positron emission tomography with injection of methionine as a prognostic factor in glioma (2001) J Neurosurg, 95, p. 746
Kameyama, M., Shirane, R., Itoh, J., The accumulation of 11C-methionine in cerebral glioma patients studied with PET (1990) Acta Neurochir (Wien), 104, p. 8
Kato, T., Shinoda, J., Nakayama, N., Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron- emission tomography (2008) AJNR Am J Neuroradiol, 29, p. 1176
Ceyssens, S., Van Laere, K., De Groot, T., [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence (2006) AJNR Am J Neuroradiol, 27, p. 1432
Moulin-Romsee, G., D'Hondt, E., De Groot, T., Non-invasive grading of brain tumours using dynamic amino acid PET imaging: Does it work for 11C-methionine? (2007) Eur J Nucl Med Mol Imaging, 34, p. 2082
Stockhammer, F., Plotkin, M., Amthauer, H., Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas (2008) J Neurooncol, 88, p. 205
Popperl, G., Krethfw, Mehrkens, J.H., FET PET for the evaluation of untreated gliomas: Correlation of FETuptake and uptake kinetics with tumour grading (2007) Eur J Nucl Med Mol Imaging, 34, p. 1933
Alavi, J.B., Alavi, A., Chawluk, J., Positron emission tomography in patients with glioma (1988) A Predictor of Prognosis. Cancer, 62, p. 1074
Patronas, N.J., Brooks, R.A., Delapaz, R.L., Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas (1983) AJNR Am J Neuroradiol, 4, p. 533
De Witte, O., Levivier, M., Violon, P., Prognostic value positron emission tomography with [18F]fluoro- 2-deoxy-D-glucose in the low-grade glioma (1996) Neurosurgery, 39, p. 470
Kruer, M.C., Kaplan, A.M., Etzl Jr., M.M., The value of positron emission tomography and proliferation index in predicting progression in lowgrade astrocytomas of childhood (2009) J Neurooncol, 95, p. 239
Floeth, F.W., Pauleit, D., Sabel, M., Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma (2007) J Nucl Med, 48, p. 519
Hanson, M.W., Glantz, M.J., Hoffman, J.M., FDGPET in the selection of brain lesions for biopsy (1991) J Comput Assist Tomogr, 15, p. 796
Pirotte, B., Goldman, S., Bidaut, L.M., Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy (1995) Acta Neurochir (Wien), 134, p. 79
Pirotte, B., Goldman, S., Massager, N., Comparison of 18F-FDG and 11C-methionine for PETguided stereotactic brain biopsy of gliomas (2004) J Nucl Med, 45, p. 1293
Pirotte, B.J., Lubansu, A., Massager, N., Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors (2007) J Neurosurg, 107, p. 392
Maier, H., Ofner, D., Hittmair, A., Classic, atypical, and anaplastic meningioma: Three histopathological subtypes of clinical relevance (1992) J Neurosurg, 77, p. 616
Cremerius, U., Bares, R., Weis, J., Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET (1997) J Nucl Med, 38, p. 26
Di Chiro, G., Hatazawa, J., Katz, D.A., Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study (1987) Radiology, 164, p. 521
Lee, J.W., Kang, K.W., Park, S.H., 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma (2009) Eur J Nucl Med Mol Imaging, 36, p. 1574
Giovacchini, G., Fallanca, F., Landoni, C., C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: An initial experience (2009) Clin Nucl Med, 34, p. 7
Plowman, P.N., Stereotactic radiosurgery. VIII. The classification of postradiation reactions (1999) Br J Neurosurg, 13, p. 256
Patronas, N.J., Di Chiro, G., Brooks, R.A., Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain (1982) Radiology, 144, p. 885
Chao, S.T., Suh, J.H., Raja, S., The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery (2001) Int J Cancer, 96, p. 191
Gomez-Rio, M., Rodriguez-Fernandez, A., Ramos- Font, C., Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence (2008) Eur J Nucl Med Mol Imaging, 35, p. 966
Kahn, D., Follett, K.A., Bushnell, D.L., Diagnosis of recurrent brain tumor: Value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET (1994) AJR Am J Roentgenol, 163, p. 1459
Alexiou, G.A., Tsiouris, S., Kyritsis, A.P., Glioma recurrence versus radiation necrosis: Accuracy of current imaging modalities (2009) J Neurooncol, 95, p. 1
Terakawa, Y., Tsuyuguchi, N., Iwai, Y., Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy (2008) J Nucl Med, 49, p. 694
Van Laere, K., Ceyssens, S., Van Calenbergh, F., Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value (2005) Eur J Nucl Med Mol Imaging, 32, p. 39
Mehrkens, J.H., Popperl, G., Rachinger, W., The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment (2008) J Neurooncol, 88, p. 27
Rachinger, W., Goetz, C., Popperl, G., Positron emission tomography with O-(2-[18F]fluoroethyl)-ltyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas (2005) Neurosurgery, 57, p. 505
Yamamoto, Y., Wong, T.Z., Turkington, T.G., 3′-Deoxy-3′-F18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: Comparison with Gd-DTPA enhanced magnetic resonance imaging (2006) Mol Imaging Biol, (8), p. 340
Maher, E.A., McKee, A., Neoplasms of the central nervous system (2003) Atlas of Diagnostic Oncology, pp. 403-415. , Skarin AT, editor. London: Elsevier Science Limited
Francavilla, T.L., Miletich, R.S., Di Chiro, G., Positron emission tomography in the detection of malignant degeneration of low-grade gliomas (1989) Neurosurgery, 24, p. 1
Ullrich, R.T., Kracht, L., Brunn, A., Methyl-L-11Cmethionine PET as a diagnostic marker for malignant progression in patients with glioma (2009) J Nucl Med, 50, p. 1962
Piroth, M.D., Pinkawa, M., Holy, R., Integratedboost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - A dosimetric comparison (2009) Radiat Oncol, 4, p. 57
Douglas, J.G., Stelzer, K.J., Mankoff, D.A., [F18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure (2006) Int J Radiat Oncol Biol Phys, 64, p. 886
Tralins, K.S., Douglas, J.G., Stelzer, K.J., Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: Prognostic information and possible role in definition of target volumes in radiation dose escalation (2002) J Nucl Med, 43, p. 1667
Grosu, A.L., Weber, W.A., Riedel, E., L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy (2005) Int J Radiat Oncol Biol Phys, 63, p. 64
Mahasittiwat, P., Mizoe, J.E., Hasegawa, A., L-[METHYL-11C] methionine positron emission tomography for target delineation in malignant gliomas: Impact on results of carbon ion radiotherapy (2008) Int J Radiat Oncol Biol Phys, 70, p. 515
Weber, D.C., Zilli, T., Buchegger, F., [18F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma (2008) Radiat Oncol, 3, p. 44
Gehler, B., Paulsen, F., Oksuz, M.O., [68Ga]-DOTATOC- PET/CT for meningioma IMRT treatment planning (2009) Radiat Oncol, 4, p. 56
Milker-Zabel, S., Zabel-Du Bois, A., Henze, M., Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET (2006) Int J Radiat Oncol Biol Phys, 65, p. 222
Rutten, I., Cabay, J.E., Withofs, N., PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: Initial report (2007) J Nucl Med, 48, p. 720
Grosu, A.L., Weber, W.A., Astner, S.T., 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy (2006) Int J Radiat Oncol Biol Phys, 66, p. 339
Stupp, R., Mason, W.P., Van Den Bent, M.J., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (2005) N Engl J Med, 352, p. 987
Brock, C.S., Young, H., O'Reilly, S.M., Early evaluation of tumour metabolic response using [18F] fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas (2000) Br J Cancer, 82, p. 608
Charnley, N., West, C.M., Barnett, C.M., Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy (2006) Int J Radiat Oncol Biol Phys, 66, p. 331
Wyss, M., Hofer, S., Bruehlmeier, M., Early metabolic responses in temozolomide treated lowgrade glioma patients (2009) J Neurooncol, 95, p. 87
Backes, H., Ullrich, R., Neumaier, B., Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1960-1967
Chen, W., Delaloye, S., Silverman, D.H., Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study (2007) J Clin Oncol, 25, p. 4714
Herholz, K., Amino acid PET and clinical management of glioma patients (2010) Eur J Nucl Med Mol Imaging, 37, pp. 683-684
